Search

Your search keyword '"Gonzalez-Billalabeitia, Enrique' showing total 9 results
Start Over Author "Gonzalez-Billalabeitia, Enrique Journal annals of oncology
9 results on '"Gonzalez-Billalabeitia, Enrique'

1. 625P TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer

Author

J. Carles Galceran, O. Reig Torras, D. Herrero Rivera, Begoña Mellado, L. Ferrer, C. Aversa, Natalia Jiménez, Leonardo Rodriguez-Carunchio, S. Cros Costa, M. Figols Gorina, A. Font Pous, Alejo Rodriguez-Vida, S. Diaz-Mercedes, M. Domenech Santasusana, D. Jiménez-Peralta, Enrique Gonzalez-Billalabeitia, Mercedes Marín-Aguilera, M.A. Climent Duran, Isabel Chirivella, and C. Suarez Rodriguez

Subjects
Hormone sensitive prostate cancer, Oncology, business.industry, Cancer research, Medicine, Hematology, business, Erg, TMPRSS2
Published
2021

2. 606P Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results

Author

O. Fernandez Calvo, R. Villatoro, V. Castillo-Morales, David Olmos, N. Sanchez-Soler, N. Romero Laorden, David Lorente, P. Borrega, Javier Puente, Raquel Luque, Enrique A. Castro, S. Ros Martínez, F. Lopez Campos, Anselmo Enrique Ferrer Hernández, G. De Velasco, A. Fernandez-Freire, R. Lozano Mejorada, Enrique Gonzalez-Billalabeitia, Nuria Lainez, and Urbano Anido

Subjects
Radium-223, Oncology, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Bone remodeling, Prostate cancer, Castration Resistance, Serum biomarkers, Internal medicine, medicine, business, medicine.drug
Published
2021

3. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

Author

Bellmunt Molins, Joaquim, 1959, Kerst, Jan Martin, Vázquez, Francisca, Morales-Barrera, Rafael, Grande, Enrique, Medina, Ana, González Graguera, M.B., Rubio, Gabriel, Anido, Urbano, Fernández Calvo, Ovidio, González-Billalabeitia, Enrique, Van den Eertwegh, Alfons Johannes M., Pujol, E., Perez-Gracia, Jose Luis, González Larriba, José Luis, Collado, R., Los, Maartje, Maciá, Sonia, De Wit, R., SOGUG, DUOS, Medical Oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, and Internal medicine

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Time Factors, medicine.medical_treatment, Phases of clinical research, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Urothelial cancer, Aparell urinari -- Càncer, Aged, 80 and over, Cabazitaxel, Vinflunine, Liver Neoplasms, Hematology, Middle Aged, Europe, Treatment Outcome, Transitional cell carcinoma, Docetaxel, 030220 oncology & carcinogenesis, Disease Progression, Female, Taxoids, medicine.drug, Adult, medicine.medical_specialty, Urology, Antineoplastic Agents, Vinblastine, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Progression-free survival, Adverse effect, Survival analysis, Aged, Carcinoma, Transitional Cell, Taxane, business.industry, Immunotherapy, medicine.disease, Survival Analysis, Surgery, 030104 developmental biology, Urinary Bladder Neoplasms, chemistry, Urothelium, business
Abstract

285 Background: Despite the advent of immunotherapy in urothelial cancer, there is still a need to find effective cytotoxic agents beyond first line. Vinflunine is EMA approved and used in several European countries. Docetaxel is widely used in second line. Cabazitaxel is a taxane with clinical activity in docetaxel-refractory cancers. A randomised study was conducted to compare its efficacy vs vinflunine. Methods: This was a multicenter, randomised, open-label, phase II/III study, following a Simon’s optimal method with early stopping rules based on an interim futility analysis. The study (NCT01830231) was supported by a research grant from Sanofi. The trial was aiming at superiority of cabazitaxel compared to vinflunine in patients progressing to platinum. ECOG, anemia and liver metastases were stratification factors. The primary objective for the phase II study was overall response rate (ORR), and overall survival (OS) for the phase III. Secondary objectives included safety and progression free survival (PFS). Results: 70 patients were included in the phase II across 19 institutions in Europe. Baseline characteristics were well balanced between the two arms. Mean age 63 years; 56 (80%) were men. No statistically significant differences were detected between arms for ORR (p=0.26). Three patients (13%) obtained a partial response on cabazitazel (95% CI, 2.7–32.4) and six patients (30%) in the vinflunine arm (95% CI, 11.9–54.3). Median PFS for cabazitaxel was 1.9 months versus 2.9 months for vinflunine (p=0.039). The study did not proceed to phase III since the futility analysis showed a lack of efficacy of cabazitaxel. A trend for OS benefit was found favouring vinflunine (median 7.6 versus 5.5 months). Grade 3-4 related adverse events were seen in 41% patients with no difference between arms. The most frequent toxicities associated with cabazitaxel were asthenia, diarrhea, anemia and febrile neutropenia. Conclusions: This phase II/III second line bladder trial comparing cabazitaxel with vinflunine was closed early when the phase II showed a lack of efficacy of the cabazitaxel arm. Vinflunine results were consistent with those observed in the phase III. Clinical trial information: NCT01830231.

Published
2017

4. 789P A differential gene expression signature identifies a population of stage I testicular non-seminomatous germ cell tumours (NSGCT) at high risk of relapse

Author

Marc Saez, A. Garrido, J. García del Muro, Juan Antonio Gil Pascual, Enrique Gonzalez-Billalabeitia, M. del Rey, Maria Jose Mendez, Alfonso Sánchez-Muñoz, L. Galvez-Carvajal, M.R. Chica-Parrado, J. Terrasa Pons, Andrés Moya, M. Luengo, Martina Alvarez, E. Alba Linero, Á. Santoja, Jorge Aparicio, J. Montes, and Emilio Alba

Subjects
education.field_of_study, business.industry, Population, Hematology, medicine.anatomical_structure, Oncology, Gene expression, Cancer research, Medicine, Relapse risk, business, Signature (topology), education, Germ cell
Published
2020

7. Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study)

Author

Elena Vallespín, A. Montesa, L. Magraner, S. Hernando Polo, José Carlos Villa-Guzmán, E. Castro Marcos, Pablo Lapunzina, R. Villatoro, N. Romero Laorden, D. Olmos Hidalgo, J. Garde, Alejo Rodriguez-Vida, B. Perez Valderrama, G. Grau, Enrique Gonzalez-Billalabeitia, J.M. Piulats Rodriguez, D. Lorente Estelles, J.A. Arranz Arija, Kristina Ibáñez, and R. Lozano Mejorada

Subjects
Genetics, Oncology, medicine.medical_specialty, business.industry, DNA repair, 030232 urology & nephrology, Hematology, Castration resistant, medicine.disease, Germline, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Cohort, Medicine, Clinico pathological, business
Published
2017

8. PROSENZA: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with enzalutamide (ENZ)

Author

Teresa Garcés, R. Morales Barrera, E. Velez, Alejo Rodriguez-Vida, P. Borrega, D. Olmos Hidalgo, R. Villatoro, Fredy López, Rosa Querol, S. Hernando Polo, E. Castro Marcos, N. Romero Laorden, G. Grau, Enrique Gonzalez-Billalabeitia, G. De Velasco, F.J. Vazquez Mazon, A. Montesa, Montserrat Domenech, Ada M. Medina, and M.A. Gonzalez Del Alba Baamonde

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, chemistry, Internal medicine, Enzalutamide, Medicine, Multi centre, business
Published
2017

9. A risk assessment model for predicting venous thromboembolic events in chemotherapy-treated germ-cell cancer

Author

Mireia Margeli, Pablo Maroto, N. Sobrevilla, S. Ros, E. Buxo, A. Fernández Aramburu, Marta Espinosa, Daniel Castellano, David Hervás, P. Jimenez Fonseca, A. Sánchez Muñoz, A. Saenz, Jorge Aparicio, Javier Sastre, J. Guma I Padro, X. Garcia del Muro, Maria Isabel Luengo, Jose Aguilar, Enrique Gonzalez-Billalabeitia, and C. Valverde Morales

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Germ cell cancer, business.industry, medicine.medical_treatment, Internal medicine, medicine, Hematology, business, Risk assessment
Published
2016

Catalog

Books, media, physical & digital resources
See catalog results